ANGPT2 and neoplasm: Combined blockade of ANGPT2 and VEGFA with a bispecific antibody (A2V) showed superior therapeutic efficacy compared with single agents in genetically engineered and transplanted tumor models, including metastatic breast cancer, pancreatic neuroendocrine tumors, and melanoma models.